HA15 is primarily used in research settings as an inhibitor of the GRP78 protein, which plays a key role in endoplasmic reticulum (ER) stress in cancer cells. By inhibiting GRP78, HA15 reduces cancer cell survival and enhances sensitivity to chemotherapy. It has shown potential in inhibiting the proliferation of certain types of cancer, including skin, breast, and pancreatic cancers, by targeting specific cellular pathways and inducing apoptosis in malignant cells. Researchers are exploring its ability to overcome drug resistance in cancer treatments, offering a promising avenue for developing more effective therapeutic strategies. Its application is currently limited to laboratory studies, with ongoing research to better understand its mechanisms and potential clinical benefits.